Drugs in MeSH Category Anti-Arrhythmia Agents

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ani Pharms	INNOPRAN XL	propranolol hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021438-002	Mar 12, 2003	BX	RX	Yes	Yes
King Pharms	PROCANBID	procainamide hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020545-001	Jan 31, 1996		DISCN	No	No
Uswm	CORGARD	nadolol	TABLET;ORAL	018063-003	Approved Prior to Jan 1, 1982		DISCN	No	No
Baxter Hlthcare	NEXTERONE	amiodarone hydrochloride	INJECTABLE;INJECTION	022325-001	Dec 24, 2008		DISCN	Yes	No			Y
Nostrum Labs	ATENOLOL	atenolol	TABLET;ORAL	074127-002	Feb 21, 1995		DISCN	No	No
Chartwell Rx	ATENOLOL	atenolol	TABLET;ORAL	074265-001	Feb 28, 1994		DISCN	No	No

Market Dynamics and Patent Landscape for Anti-Arrhythmia Agents (NLM MeSH Class)

Last updated: July 5, 2026

Anti-arrhythmia agents in the NLM MeSH Class are a high-modulation, competitive segment with uneven patent coverage across subclasses (Class I sodium channel blockers, Class II beta blockers, Class III potassium channel blockers, Class IV calcium channel blockers, and assorted rhythm-control agents). Market share and R&D spend cluster around atrial fibrillation (AF) and ventricular arrhythmias, while patent estates and FDA exclusivity primarily hinge on (1) active ingredient composition, (2) formulation and pharmacokinetic variants (including extended release), and (3) method-of-use (notably AF indications and specific dosing regimens). Competitive risk is concentrated in molecules with expiring composition patents and minimal downstream barriers, while higher barriers exist where extended-release, low-dose, or combination fixed-dose products have multiple overlapping patents and where FDA exclusivity is stacked.

---

What patents protect anti-arrhythmia agents in NLM MeSH Class, and how many patents cover each drug?

Featured snippet answer: Anti-arrhythmia patent coverage typically spans composition-of-matter, polymorph/solvate and salt claims, formulation (especially extended release), and method-of-use for arrhythmia subtypes. The largest estates usually attach to AF rhythm-control products with multiple oral or injectable presentations, not to older single-compound generics.

Which patent categories dominate anti-arrhythmia estates?

1. Composition of matter
   • Active ingredient (salt/form, free base, enantiomer where applicable).
   • Polymorph and crystalline form claims (common for Class III agents with complex solid-state behavior).
2. Formulation and delivery
   • Extended-release matrices, osmotic pumps, multiparticulate systems.
   • Bioavailability and exposure window claims (where supported by data).
3. Methods of use
   • AF or atrial flutter rhythm-control and prevention of recurrence.
   • Specific ventricular rate control vs rhythm control distinctions.
   • Dose titration and titration schedules (where claims are supported).
4. Manufacturing
   • Process claims tied to specific crystallization or drying conditions.
5. Second medical use and combination regimens
   • Fixed-dose combinations or coadministration claims, frequently litigated because the commercial product is a single marketed dosage form.

Where patent density tends to be highest?

• Oral anti-arrhythmics with solid-state engineering and controlled-release needs (lower dose windows, GI tolerability, QT-prolongation management).
• AF-focused products with multiple label updates that enable method-of-use claim targeting.
• Injectables and infusion formulations where pH/solvent system patents add manufacturing barriers even after composition expiration.

---

When does exclusivity end for key anti-arrhythmia agents, and what timeline drives generic or biosimilar risk?

Featured snippet answer: Exclusivity and patents often align such that the earliest generic risk window starts 18 months before the relevant “true” effective patent expiration, but real entry is delayed by remaining formulation/method-of-use patents and by FDA labeling bottlenecks.

Typical exclusivity stack structure in anti-arrhythmia drugs

• New chemical entity (NCE) exclusivity: 5 years post-approval.
• Orphan drug exclusivity (only for qualified indications): 7 years post-approval.
• Pediatric exclusivity: 6 months added via pediatric study requests/completed trials.
• Orphan + pediatric stacking: extends the effective time to generic substitution in practice.

Patent expiration mechanics that matter for this category

• Composition patents often set the “first window.”
• Formulation and method-of-use patents can preserve market exclusivity even after composition expiry by requiring “carve-outs” or non-infringing designs.
• Orange Book listing structures: some anti-arrhythmia products list multiple patents tied to multiple strengths or dosage forms, which can block launch even if one strength becomes vulnerable.

(Note: This response requires molecule-by-molecule FDA/Orange Book data to give precise dates and patent counts. Without specific active ingredients, no complete and accurate exclusivity timeline can be produced.)

---

What Orange Book status applies to anti-arrhythmia drugs, and how do patent listings differ by dosage form?

Featured snippet answer: Orange Book listings for anti-arrhythmia products are frequently dosage-form specific (tablet strength, extended-release bead system, injectable concentration). Patent listing granularity creates uneven generic launch readiness by strength.

Common Orange Book patterns in anti-arrhythmia portfolios

• Extended-release tablets/capsules
  • Higher frequency of formulation patents.
  • Multiple listed patents tied to release mechanism and bioavailability targets.
• Immediate-release oral tablets
  • More likely to rely on composition patents and fewer formulation barriers.
• Injectables/infusion solutions
  • Orange Book entries sometimes include solvent system and pH-related patents that survive beyond composition.

---

How strong is the patent estate for anti-arrhythmia drugs, and what metrics predict litigation outcomes?

Featured snippet answer: Patent estates are strongest where there are multiple overlapping claim families that map cleanly onto the marketed dose form and indication, especially when method-of-use claims are tethered to dose titration protocols.

Litigation-amenable features in this class

• Claims that read directly onto the marketed formulation
  • Where formulation patents cover release kinetics or excipient system, design-arounds are harder.
• Method-of-use claims aligned to the approved label
  • When a claim matches an indication that remains in the label, Paragraph IV carve-outs are narrower.
• Multiple jurisdictions with harmonized claims
  • European and UK enforcement can raise settlement leverage even when US entry is delayed.

Metrics used in practice to gauge enforceability leverage

• Number of Orange Book patents per NDA/BLA and per dosage strength.
• Breadth of claims (genus vs species).
• Prosecution history signals (narrowing amendments close to approval).
• Prior art burden for obviousness arguments on polymorph and formulation claims.
• Ability to “skinny label” versus needing “non-infringing product” redesign.

---

What patent litigation affects anti-arrhythmia agents, including Paragraph IV challenges and settlements?

Featured snippet answer: Patent litigation in anti-arrhythmia drugs concentrates on Paragraph IV filings challenging listed patents for composition and formulation, with settlements typically focused on delayed launch, labeling carve-outs, and at times agreed design changes.

How Paragraph IV risk materializes in this category

• Carve-out strategy
  • Generic challengers often target indication-specific method-of-use patents via label limitations.
• Design-around strategy
  • Extended-release systems invite formulation redesigns, but only if the generic can maintain exposure and safety profile.
• Settlement structure
  • Common elements:
    • Launch date commitments (delayed entry).
    • Provision of a permitted generic launch “at risk” for non-blocked strengths.
    • Agreement on labeling language for the blocked indication(s).

(Note: Specific cases, docket numbers, and settlement dates are not included because the prompt does not specify which active ingredients to analyze. Providing case-level facts without molecule scope would be incomplete.)

---

How do anti-arrhythmia drugs compare in patent durability: Class I, II, III, and IV agents?

Featured snippet answer: Patent durability varies more by product formulation and label breadth than by ion-channel class alone. AF rhythm-control products generally show longer downstream coverage than older, single-claim legacy agents.

Comparative durability drivers by subclass

• Class I sodium channel blockers
  • Often older, but some products maintain coverage through updated formulations and targeted dosing regimens.
• Class II beta blockers
  • Many are older and off-patent in developed markets; durability tends to come from fixed-dose combinations and new AF/heart failure label stratifications.
• Class III potassium channel blockers
  • Solid-state and formulation engineering can extend enforceability (polymorphs, controlled-release variants).
• Class IV calcium channel blockers
  • Durability is driven by controlled-release and combination presentations, not by core chemistry alone.

---

What formulations are protected for anti-arrhythmia agents, and what generic entry risks exist?

Featured snippet answer: Formulation patents are the most common downstream entry barrier after composition expiry, especially for extended-release, polymorph-specific solids, and injectables with specific solvent/pH systems.

Formulation protection that blocks generic “at launch”

• Extended-release release profile
  • Release kinetics and bioavailability window patents.
• Polymorph and solid-state selection
  • Different forms can keep the claimed product protected even if the active ingredient is otherwise generic.
• Dose-dependent exposure claims
  • When method/formulation patents target a specific exposure range to manage QT-risk or tolerability.

Generic entry risk map (conceptual)

• Low barrier: immediate-release legacy actives with limited reformulation claims.
• Medium barrier: multiple polymorph and strength-specific formulation patents.
• High barrier: extended-release plus method-of-use stacking and multiple Orange Book listings across strengths.

(Note: A concrete risk map requires listing the specific anti-arrhythmia drugs within the MeSH category and mapping their Orange Book estates.)

---

What manufacturing/IP barriers protect anti-arrhythmia drugs during generic launches?

Featured snippet answer: Manufacturing barriers are most relevant when patents claim specific process steps that directly affect solid-state form, particle size, or controlled-release layer characteristics.

Key manufacturing-linked patent targets

• Crystallization steps
  • Fixing polymorph outcome via controlled solvents and temperatures.
• Drying and milling
  • Particle size and surface area affecting dissolution and exposure.
• Layering or matrix build
  • For extended-release formulations, patents can cover the exact build process.

---

Which companies dominate anti-arrhythmia agent IP positions, and who are the typical generic challengers?

Featured snippet answer: Brand holders tend to lead with large multi-patent estates in AF and controlled-release products, while generic challengers concentrate on molecules where composition expiry creates a near-term Paragraph IV window.

(Note: Company-by-company ranking requires a defined set of active ingredients and their Orange Book patent assignments.)

---

What is the FDA regulatory status of anti-arrhythmia drugs, and how does it shape patent challenges?

Featured snippet answer: FDA label status and pathway (505(b)(1), 505(b)(2), or ANDA) drive the probability of successful Paragraph IV challenges. Controlled-release and specific indication claims increase the need for FDA labeling carve-outs or new clinical bridging.

Pathway effects

• ANDA (generic)
  • Often triggers Paragraph IV when listed patents are present.
• 505(b)(2) (reformulation or new dose)
  • Can avoid direct infringement with a different formulation concept or relies on reference to listed patents, affecting exclusivity and patent use codes.
• Line extensions
  • New strengths or new indication filings can add new patents even when the core active ingredient is older.

---

Key Takeaways

• Anti-arrhythmia patent landscapes are driven less by ion-channel subclass and more by downstream patent stacking: extended-release/formulation, polymorph/solid-state, and indication-specific method-of-use.
• Generic entry risk concentrates where Orange Book listings are sparse after composition expiry; barriers increase when multiple overlapping patents map to multiple strengths and to label-relevant indications.
• Litigation and settlements in this class commonly resolve around delayed launch dates, labeling carve-outs for method-of-use patents, and permitted strengths or reformulation constraints.

---

FAQs

1. How do Orange Book patent listings for extended-release anti-arrhythmia tablets delay generic launch?
2. What types of method-of-use claims for atrial fibrillation are most vulnerable to “skinny label” carve-outs?
3. Which downstream patents (polymorph vs formulation vs manufacturing) most often survive after composition expiry in anti-arrhythmia drugs?
4. How do pediatric exclusivity and orphan exclusivity stack affect the practical entry timeline for generic anti-arrhythmics?
5. What settlement terms are most common in Paragraph IV cases involving formulation patents for controlled-release anti-arrhythmia products?

---

References

No specific sources were cited because the prompt did not specify active ingredients, NDA/BLA numbers, or jurisdictions, which prevents a complete and accurate Orange Book and litigation-linked patent analysis for the MeSH category as a whole.